Testing for Genetic Variants Informed the Use of Cancer Risk Assessments
Genetic testing provided important information beyond personal and family history.
Ovarian Cancer
Secondary Surgical Cytoreduction Not Superior in Ovarian Cancer
Addition of surgery prior to chemotherapy does not prolong overall survival in recurrent ovarian cancer.
Multitumor “Exceptional Responder” Program in Australia Seeks to Gain Clinical Context
The first multitumor exceptional responder program in Australia is under way, adding to the growing worldwide effort to identify patient DNA changes and biomarkers of response.
Oncologists Debate Using Maintenance Bevacizumab in Stage IIIc Ovarian Cancer
In a recent paper published in the Journal of Clinical Oncology, the authors recommended using adjuvant and maintenance bevacizumab to treat a patient with stage IIIc ovarian cancer following an optimal (R0) resection.
Zejula Approved for Late-line Treatment of Recurrent Ovarian Cancer
Zejula, a poly(ADP-ribose) polymerase (PARP) inhibitor, is also approved for maintenance treatment in adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Addition of Bevacizumab to Anti–PD-1 Therapy Improved Response Rate in Recurrent Ovarian Cancer
There is interest in determining whether antiangiogenic therapies can act synergistically with checkpoint blockade in the setting of recurrent ovarian cancer.
Maintenance Olaparib Found to Provide a PFS Benefit in Advanced Ovarian Cancer
The benefit was seen in an all-comers population, according to the presenters at ESMO Congress 2019.
Oophorectomy More Effective Than Ultrasound Screening in Preventing BRCA1-Related Ovarian Cancer
Results of a prospective study comparing effectiveness of ultrasound screening and salpingo-oophorectomy in preventing ovarian cancer are presented.
Dual-Targeted CAR-T Therapies in Solid Tumors: Q&A With Dr Wayne Marasco
Dr Marasco explains that CAR-T therapies are really “cellular therapies that work by way of gene manipulation,” and describes a method through which he hopes CAR-T can produce durable, long-term treatments for solid tumors.
Intrauterine Device Use May Reduce Incidence of Ovarian Cancer
Novel noncontraceptive benefit seen for all intrauterine devices.
Next post in Gynecologic Cancer
